Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Written By: Nitin Goswami, Senior Medical Content Writer | Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Quick answer: Elahere (mirvetuximab soravtansine) is an infusion medicine for adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have already received one to three earlier treatments. In the phase 3 MIRASOL trial, median overall survival was 16.46 months with Elahere versus 12.75 months with chemotherapy. It carries a boxed warning for eye toxicity and pneumonitis. Elahere isn't yet sold in India, but it can be accessed legally through a Named Patient Program with a valid prescription and FRα test results.
Last reviewed: September 24, 2026. Every figure in this guide is sourced in the References section at the end.
If your ovarian cancer has come back or kept growing after platinum-based chemotherapy, you've probably heard your oncologist use the term "platinum-resistant" — and you may be wondering what that actually changes. It means the cancer no longer responds well to the class of chemotherapy drugs (carboplatin or cisplatin) that usually forms the backbone of ovarian cancer treatment, which narrows the options but doesn't close them. One newer option built specifically for this situation is Elahere (mirvetuximab soravtansine), a targeted therapy for tumors that test positive for a protein called folate receptor alpha (FRα). This guide walks through what platinum resistance means, how doctors test for FRα, and how Elahere works once standard chemotherapy is no longer enough.
| Brand name | Elahere |
|---|---|
| Generic name | Mirvetuximab soravtansine |
| Drug class | Antibody-drug conjugate: a folate receptor alpha (FRα)-directed antibody linked to a microtubule inhibitor |
| Manufacturer | ImmunoGen |
| Form and dose | Injection in a 100 mg/20 mL single-dose vial, given as an intravenous infusion of 6 mg/kg (adjusted ideal body weight) every 3 weeks |
| U.S. approval | First approved in 2022 |
| Approved use | Adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three earlier systemic treatments |
| Required test | FRα status confirmed with an FDA-approved companion diagnostic (the VENTANA FOLR1 assay) |
| Boxed warning | Eye toxicity and pneumonitis (lung inflammation) |
| Key trial | MIRASOL (New England Journal of Medicine, 2023) |
| Access in India | Elahere isn't yet sold in India. It can be accessed through a Named Patient Program with a valid prescription and FRα test results (see the Elahere product page) |
Ovarian cancer — along with the closely related fallopian tube and primary peritoneal cancers, which are treated as one disease clinically — most often starts as epithelial ovarian cancer. First-line treatment almost always includes a platinum-based chemotherapy drug, because this class works better against ovarian cancer than almost any other.
Doctors classify recurrence by how long it takes to show up after your last dose of platinum chemotherapy:
This "platinum-free interval" is one of the strongest predictors doctors have for how well further treatment will work. It's why platinum resistance matters so much clinically — it signals that going back to the same drug class is unlikely to help, and outcomes with older non-platinum chemotherapy options have historically been limited.
Ovarian cancer is notoriously easy to miss early, because its symptoms often mimic everyday digestive or bladder issues:
If these symptoms are new, persistent, and happen more than about 12 times a month, it's worth raising with your doctor rather than waiting them out.
Diagnosis typically starts with a pelvic exam, a transvaginal ultrasound, and a CA-125 blood test — though CA-125 alone isn't definitive, since benign conditions can raise it too. Imaging (CT or MRI) and a tissue biopsy, usually obtained during surgery, confirm the diagnosis and cancer type. Ovarian cancer is then staged from I to IV based on how far it has spread — from confined to one or both ovaries (Stage I) to distant spread beyond the abdomen (Stage IV).
The big cancer registries publish figures for ovarian cancer as a whole; numbers specific to platinum-resistant disease come mostly from clinical trials. So this section starts with the wider picture and then narrows to what is known about resistant disease and the FRα biomarker.
The most reliable recent figures come from the phase 3 MIRASOL trial, which enrolled 453 patients with FRα-high, platinum-resistant high-grade serous ovarian cancer (Moore et al., New England Journal of Medicine, 2023):
Trial participants are carefully selected and monitored, so real-world results can differ, and a median is a midpoint for a group rather than a forecast for one person. What the numbers do show is why guiding treatment by biomarker matters once chemotherapy alone has limited options.
Not every ovarian tumor carries enough FRα to qualify. In a Canadian study that tested 1,547 ovarian carcinoma samples, high FOLR1 (FRα) expression was found in:
In other words, being platinum-resistant does not by itself mean a tumor is FRα-high — the test result is what decides.
Before Elahere can be considered, your tumor tissue needs to be tested for a specific protein.
FRα is a protein found on the surface of cells that helps them take in folate. It's overexpressed on roughly 9 out of 10 ovarian cancer cells, but only minimally present on normal tissue — which is exactly what makes it a useful target for a therapy designed to spare healthy cells.
Your pathologist tests tumor tissue using an FDA-approved companion diagnostic (the VENTANA FOLR1 assay), which looks for FRα staining on at least 75% of viable tumor cells at moderate-to-strong intensity. Only patients who test positive on this specific assay are eligible for Elahere — it's a required step, not an optional one.
Elahere belongs to a class of medicines called antibody-drug conjugates, or ADCs — essentially a guided missile built from three parts.
An ADC combines an antibody (which finds and binds a specific target on cancer cells), a linker, and a cell-killing chemotherapy payload, all in one molecule.
In Elahere's case, the antibody component recognizes and attaches to FRα on the surface of the cancer cell. The whole complex is then pulled inside the cell, where the linker releases its payload — a potent microtubule inhibitor called DM4 — which disrupts the cell's internal scaffolding and kills it. Because this only happens inside cells carrying FRα, the intent is to concentrate the chemotherapy effect on the tumor while limiting exposure to normal tissue.
Elahere is approved for adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have already received one to three prior lines of systemic treatment.
Elahere is given as an intravenous infusion once every three weeks, dosed at 6 mg/kg based on your adjusted ideal body weight (not your actual weight) — your care team calculates this for you.
The most commonly reported side effects include blurred vision, keratopathy (corneal changes), fatigue, peripheral neuropathy, nausea, diarrhea, abdominal pain, dry eye, and low blood counts. Most of these are manageable with monitoring and, when needed, dose adjustment.
Elahere carries an FDA boxed warning — its strongest safety label — covering two specific risks.
Elahere can cause visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis. Because of this, you'll need an eye exam before starting treatment, then every other cycle for the first eight cycles, and as needed afterward. Your doctor may also prescribe preventive eye drops and a cooling eye mask during the infusion. Treatment is paused until eye symptoms improve, and permanently stopped for the most severe reactions.
Severe, life-threatening, or fatal lung inflammation (pneumonitis or interstitial lung disease) can occur. Your care team will watch for new cough, shortness of breath, or low oxygen levels. Persistent moderate pneumonitis means pausing treatment and considering a lower dose; more severe cases mean stopping Elahere permanently.
Elahere can also cause peripheral neuropathy (numbness or tingling, usually in the hands or feet) and can harm a developing fetus, so effective contraception is required during treatment. Infusion-related reactions are also possible, particularly with the first dose.
Elahere is not yet commercially available in India. If your FRα test comes back positive and your oncologist recommends it, it can still be legally imported for your personal treatment through a Named Patient Program — a regulated pathway that lets a patient with a valid prescription import a medicine that isn't yet sold locally. This typically requires:
The Elahere product page outlines the current process, and our oncology access program supports the same pathway for other ovarian cancer therapies, including Zejula for maintenance treatment.
Every patient's biomarker results and treatment history look different, so the fastest way to know where you stand is to talk to someone directly. Share your FRα test results and treatment history, and our team will walk you through the prescription, documentation, and import process for your specific case, at no obligation. Get in touch with us whenever you're ready.
A platinum-resistant diagnosis is a genuine turning point in treatment, but it isn't the end of your options. FRα testing now routinely identifies patients who can benefit from a targeted approach instead of moving through older chemotherapy regimens with limited success rates, and clinical trial data has shown Elahere extending survival meaningfully compared to standard chemotherapy in this setting. Staying current with your care team on test results and symptoms — especially anything involving your eyes or breathing — is what allows this kind of targeted treatment to be used safely over time.
It means your cancer came back or kept growing within 6 months of finishing platinum-based chemotherapy, which means that drug class is less likely to work again and other options, including targeted therapies like Elahere, become more relevant.
Your tumor tissue needs to test positive for folate receptor alpha (FRα) using an FDA-approved companion diagnostic test, and you need to have already tried one to three prior lines of treatment.
It contains a chemotherapy payload, but it's delivered differently than traditional chemotherapy. Elahere is an antibody-drug conjugate that targets FRα-positive cells specifically, aiming to concentrate the chemotherapy effect on the tumor rather than exposing your whole body to it equally.
Its boxed warning covers eye toxicity (blurred vision, corneal changes, dry eye) and pneumonitis (lung inflammation), both of which require regular monitoring — eye exams on a set schedule and watchfulness for new cough or breathlessness.
No. Elahere is specifically for patients who have already received one to three prior systemic treatment regimens and whose cancer is platinum-resistant with confirmed FRα-positive status.
Through a regulated Named Patient Program, which allows import of the medicine for a specific, named patient with a valid prescription, biomarker test results, and the required documentation — a legal pathway used worldwide for medicines not yet locally marketed.
Yes — more than for most medicines. Elahere is an antibody-drug conjugate given by infusion, and biologic medicines like this depend on careful handling from the factory all the way to the infusion chair. Unverified sellers can offer counterfeit or improperly stored product that looks identical to the real thing, which is a risk no one should take with a treatment this targeted. Named Patient Program sources directly from the manufacturer or its authorized distributors, keeps full documentation and batch traceability, and follows import regulations at every step, so your treating team receives verified medicine.
This page is meant to help you understand your options and prepare for conversations with your care team. Decisions about Elahere, your FRα result, and your treatment plan belong with your own oncologist, who knows your full medical history.
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.com
Contact Us:
+91 9810469557
We get back to you shortly during our working hours.